ARCHIVES

Phase III Trial Of PARP Inhibitor BSI-201 Opens For Triple-Negative Breast Cancer

This article is from The Cancer Letter archive.

Vol. 32 No. 7 | July 31, 2009

Download PDF Visit The Full Archive

Related Articles

‘We Cannot Tolerate One Third Reduction In Centers. Prevention, Clinical Trials Programs’

September 20, 1991

Socio-Economic Factors, Access To Care, Associated With More Aggressive Cancers

April 27, 2007

‘Major Discover’ At FCRDC Is NF1 Gene, Report Says

November 30, 1990

Kington Named Acting NIH Director.

November 14, 2008

President’s Cancer Panel Special Commission On Breast Cancer Named

April 25, 1992

Trifluridine and Tipiracil Hydrochloride Increase OS, PFS in Phase III Trial

July 25, 2014